OnKure Therapeutics (OKUR) Assets Average (2021 - 2026)
OnKure Therapeutics' (OKUR) quarterly Assets Average came in at $130.4 million in Q1 2026, up 21.43% YoY from $107.4 million in Q1 2025, and up 93.26% on a QoQ basis from $67.5 million in Q4 2025.
OnKure Therapeutics (OKUR) Assets Average (2021 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 6 years of Assets Average data on file, last reported at $130.4 million in Q1 2026.
- Quarterly Assets Average rose 21.43% year-over-year to $130.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.4 million (up 21.43% YoY) and the FY2025 annual result came in at $88.5 million, up 17.51% from the prior year.
- Assets Average rose to $130.4 million in Q1 2026, from $67.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $149.2 million in Q1 2022 to a low of $60.2 million in Q1 2024.
- A 5-year average of $104.4 million and a median of $103.5 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 98.24% — and 2024, when it sank 43.84%.
- Tracing OKUR's Assets Average over 5 years: stood at $115.3 million in 2022, then retreated by 27.99% to $83.1 million in 2023, then rose by 15.91% to $96.3 million in 2024, then dropped by 29.91% to $67.5 million in 2025, then surged by 93.26% to $130.4 million in 2026.
- The last three Assets Average figures came in at $130.4 million (Q1 2026), $67.5 million (Q4 2025), and $79.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 189.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189.02 Mn |
| Mar 31, 2026 | 130.41 Mn |
| Dec 31, 2025 | 67.48 Mn |
| Sep 30, 2025 | 79.45 Mn |
| Jun 30, 2025 | 92.98 Mn |
| Mar 31, 2025 | 107.39 Mn |
| Dec 31, 2024 | 96.28 Mn |
| Sep 30, 2024 | 78.18 Mn |
| Jun 30, 2024 | 81.68 Mn |
| Mar 31, 2024 | 60.19 Mn |
| Dec 31, 2023 | 83.06 Mn |
| Sep 30, 2023 | 139.21 Mn |
| Jun 30, 2023 | 123.45 Mn |
| Mar 31, 2023 | 103.53 Mn |
| Dec 31, 2022 | 115.34 Mn |
| Sep 30, 2022 | 128.06 Mn |
| Jun 30, 2022 | 139.01 Mn |
| Mar 31, 2022 | 149.22 Mn |
| Dec 31, 2021 | 158.48 Mn |
| Sep 30, 2021 | 167.12 Mn |